CN102526473B - 一种治疗慢性乙型病毒性肝炎的药剂 - Google Patents
一种治疗慢性乙型病毒性肝炎的药剂 Download PDFInfo
- Publication number
- CN102526473B CN102526473B CN2012100755695A CN201210075569A CN102526473B CN 102526473 B CN102526473 B CN 102526473B CN 2012100755695 A CN2012100755695 A CN 2012100755695A CN 201210075569 A CN201210075569 A CN 201210075569A CN 102526473 B CN102526473 B CN 102526473B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicament
- hepatitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 230000001684 chronic effect Effects 0.000 title claims abstract description 13
- 241000700605 Viruses Species 0.000 title abstract description 7
- 208000006454 hepatitis Diseases 0.000 title abstract description 7
- 231100000283 hepatitis Toxicity 0.000 title abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 10
- 210000003038 endothelium Anatomy 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 241001530126 Scrophularia Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 abstract description 6
- 241000405414 Rehmannia Species 0.000 abstract 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 241000596154 Belamcanda Species 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 241000123069 Ocyurus chrysurus Species 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000972672 Phellodendron Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 240000005860 Portulaca grandiflora Species 0.000 abstract 1
- 244000081426 Ranunculus ficaria Species 0.000 abstract 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 206010019799 Hepatitis viral Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 201000001862 viral hepatitis Diseases 0.000 description 6
- 229940046011 buccal tablet Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- -1 absorption carrier Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗慢性乙型病毒性肝炎的药剂，它是由下述重量配比的物质制成：蒲公英3-5份、麦冬1-3份、熟地黄1-3份、车前子2-5份、茵陈0.1-0.5份、黄柏1-3份、枸杞2-5份、桔梗1-3份、当归3-5份、生地3-5份、鸡内金1-3份、半枝莲5-8份、射干1-3份、玄参1-3份、白芍3-5份和茜草1-3份。本发明所述的治疗慢性乙型病毒性肝炎的口含片的全部成分都是天然材料，安全性较好，适于在临床上大规模推广。
Description
技术领域
本发明涉及医药领域，具体来说涉及一种治疗慢性乙型病毒性肝炎的药剂。
背景技术
慢性病毒性乙型肝炎是指感染乙型肝炎病毒半年以上，病毒没有得到彻底清除，体内乙肝病毒潜伏或引起肝炎发病。慢性乙型肝炎可以有明确的急性乙肝演变而来；半年前有过急性黄疸型或无黄疸型肝炎发作病史，治疗或自愈不彻底，留下祸根潜伏下来，半年后，或多年后，再次发病。也因婴幼儿时期感染了乙肝病毒，当时由于免疫功能尚不健全和完善，不能将病毒清除，病毒潜伏于肝脏，经过长期的免疫耐受期的沉寂后，大约到了青壮年期，便开始发病。首次发病很象急性肝炎，有的首次发病就已经是肝硬化了。
对于治疗慢性病毒性乙型肝炎的药物的需要日益增强。
发明内容
本发明的目的是提供一种治疗慢性乙型病毒性肝炎的药剂。
为了实现本发明的目的，本发明提供一种治疗慢性乙型病毒性肝炎的药剂，它是由下述重量配比的物质制成：蒲公英3-5份、麦冬1-3份、熟地黄1-3份、车前子2-5份、茵陈0.1-0.5份、黄柏1-3份、枸杞2-5份、桔梗1-3份、当归3-5份、生地3-5份、鸡内金1-3份、半枝莲5-8份、射干1-3份、玄参1-3份、白芍3-5份和茜草1-3份。
优选地，本发明所述的治疗慢性乙型病毒性肝炎的药剂是由下述重量配比的物质制成：蒲公英3份、麦冬2份、熟地黄3份、车前子2份、茵陈0.3份、黄柏2份、枸杞4份、桔梗2份、当归4份、生地3份、鸡内金2份、半枝莲6份、射干2份、玄参2份、白芍4份和茜草1份。
优选地，所述药剂为片剂、口含片、胶囊剂或口服液。
可以采用本领域技术人员熟知的方法来进行药剂的制备。根据需要，可以加入各种药学上可接受的载体。所述的载体包括药学领域常规的稀释剂、赋形剂、填充剂、粘合剂、湿润剂、崩解剂、吸收促进剂、表面活性剂、吸附载体、润滑剂等。本发明的口含片在制备时，可选择的填充剂有：淀粉、糖粉、磷酸钙、糊精、微晶纤维素、乳糖、预胶化淀粉、甘露醇等；可选择的粘合剂有：羧甲基纤维素钠、PVP-K30、羟丙基纤维素、淀粉浆、甲基纤维素、乙基纤维素、羟丙基甲基纤维素、胶化淀粉等；可选择的崩解剂有：干淀粉、交联聚维酮、交联羧甲基纤维素钠、羧甲基淀粉钠、低取代羟丙基纤维素等；可选择的润滑剂有：硬脂酸镁、滑石粉、十二烷基硫酸钠、微粉硅胶等。
本发明所述的治疗慢性乙型病毒性肝炎的药剂的全部成分都是天然材料，安全性较好，适于在临床上大规模推广。
具体实施方式
下面通过实施例进一步说明本发明。应该理解的是，本发明的实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护的范围。除非另有说明，否则本发明中的百分数是重量百分数。
实施例1本发明的口含片的制备
称取蒲公英30克、麦冬20克、熟地黄30克、车前子20克、茵陈3克、黄柏20克、枸杞40克、桔梗20克、当归40克、生地30克、鸡内金20克、半枝莲60克、射干20克、玄参20克、白芍40克和茜草10克，粉碎，过80目筛。然后称取糖粉40克，过80目筛，和上述原料混合。用5重量％的HPMC水溶液作粘合剂制软材，制粒(用16目尼龙筛制粒二遍)，在60℃下干燥2-3个小时，用16目的尼龙筛整粒。再加入30克的羧甲基淀粉钠和1克的硬脂酸镁，混匀，用直径14mm的冲头压片100片。
实验例
诊断标准
参照2000年9月中华医学会传染病与寄生虫病毒学分会，肝病学会，西安会议联合修订的《病毒性肝炎防治方案》(中华医学会传染与寄生虫学会.肝病学分会·病毒性肝炎防治方案[J].中华肝脏病杂志，2000·8(6)：324-3290)及《中药新药临床研究指导原则》(郑筱萸，任德权，曹文庄等.中药新药临床研究指导原则[[S].北京，中国医药科技出版社，2002·143-151)来选择患者共40例，其中男25例，女15例，年龄30-50岁，平均39岁，平均病程2.5年。
排除标准
①同时或重叠感染甲型、丙型等其它类型的肝炎病毒患者；②经检查证实由药物中毒，乙醇中毒等因素所致的肝炎及自身免疫性肝炎；③合并肝癌，肝性脑病，失代偿期肝硬化以及严重的心脑血管，肺，肾，内分泌和造血系统严重原发性疾病，精神病患者。④妊娠妇女，哺乳期妇女。⑤过敏体质或多种药物过敏者。10岁以下的儿童不能服中药者。
治疗方法
使用实施例1中制备口含片对于上述患者进行治疗。患者舌下含上述口含片，一日两次，每次一片。以三个月为一个疗程，连续进行两个疗程。
疗效评定标准
参照中华医学会传染病与寄生虫病分会，肝病学会西安会议联合修订的《病毒性肝炎防治方案》与国家药物监督管理局(2002年)中药新药治疗病毒性肝炎的临床研究指导原则标准：①临床控制：临床症状消失，肝功能正常，表面抗原转阴或表面抗体阳性，肝胆脾彩超无异常，HBV-DNA(定量)小于103②显效：临床症状消失或轻微，肝功能正常，e抗原转阴，肝胆脾彩超无异常或轻微异常，HBV-DNA(定量)小于103③有效：临床症状减轻，肝功能损害B超检查病情分度标准好转1至2个等级。④无效：没有坚持治疗，失访，恶化，死亡的。
结果
经过治疗，发现全部患者均符合临床控制的标准。并且在治疗过程中进行跟踪观察，未发现明显的不良反应。
Claims (2)
1.一种治疗慢性乙型病毒性肝炎的药剂，其特征在于，它是由下述重量配比的物质制成：蒲公英3份、麦冬2份、熟地黄3份、车前子2份、茵陈0.3份、黄柏2份、枸杞4份、桔梗2份、当归4份、生地3份、鸡内金2份、半枝莲6份、射干2份、玄参2份、白芍4份和茜草1份。
2.根据权利要求1所述的治疗慢性乙型病毒性肝炎的药剂，其特征在于，所述药剂为片剂、胶囊剂或口服液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100755695A CN102526473B (zh) | 2012-03-21 | 2012-03-21 | 一种治疗慢性乙型病毒性肝炎的药剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100755695A CN102526473B (zh) | 2012-03-21 | 2012-03-21 | 一种治疗慢性乙型病毒性肝炎的药剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526473A CN102526473A (zh) | 2012-07-04 |
| CN102526473B true CN102526473B (zh) | 2013-05-29 |
Family
ID=46335293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100755695A Expired - Fee Related CN102526473B (zh) | 2012-03-21 | 2012-03-21 | 一种治疗慢性乙型病毒性肝炎的药剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526473B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6605036B2 (ja) | 2014-11-15 | 2019-11-13 | 广西慧宝源医▲薬▼科技有限公司 | 肝臓及び腎臓の損傷関連疾患を予防し又は治療する中医薬組成物の調製法 |
| CN108498739A (zh) * | 2018-06-26 | 2018-09-07 | 桐城市泰安中药材种植专业合作社 | 一种治疗慢性肝炎的中药及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428114A (zh) * | 2008-11-06 | 2009-05-13 | 李念 | 一种治疗慢性乙肝、肝硬化和肝腹水的药物 |
| CN101612360A (zh) * | 2009-07-17 | 2009-12-30 | 肖嘉惠 | 治疗肝炎、肝硬化、肝癌的药物 |
| CN101773656A (zh) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | 一种抗乙肝纳米中药及其生产方法 |
| CN101837065A (zh) * | 2010-05-13 | 2010-09-22 | 粤北人民医院 | 抗肝炎、抗肿瘤及提高机体免疫功能的药物及其制备方法 |
| CN101940758A (zh) * | 2010-08-19 | 2011-01-12 | 王尚瑞 | 一种治疗肝病的中药组合物及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116890C (zh) * | 2000-12-26 | 2003-08-06 | 陈玉周 | 一种治疗乙肝的药物 |
| CN1562160A (zh) * | 2004-04-21 | 2005-01-12 | 金海清 | 治疗乙型肝炎并发症组方药物 |
-
2012
- 2012-03-21 CN CN2012100755695A patent/CN102526473B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428114A (zh) * | 2008-11-06 | 2009-05-13 | 李念 | 一种治疗慢性乙肝、肝硬化和肝腹水的药物 |
| CN101773656A (zh) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | 一种抗乙肝纳米中药及其生产方法 |
| CN101612360A (zh) * | 2009-07-17 | 2009-12-30 | 肖嘉惠 | 治疗肝炎、肝硬化、肝癌的药物 |
| CN101837065A (zh) * | 2010-05-13 | 2010-09-22 | 粤北人民医院 | 抗肝炎、抗肿瘤及提高机体免疫功能的药物及其制备方法 |
| CN101940758A (zh) * | 2010-08-19 | 2011-01-12 | 王尚瑞 | 一种治疗肝病的中药组合物及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526473A (zh) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657821B (zh) | 一种治疗卵巢囊肿的药剂 | |
| CN106177675A (zh) | 一种治疗椎管狭窄及骨折的中药膏贴 | |
| CN105012720A (zh) | 一种治疗骨病的中药组合物 | |
| CN102688387B (zh) | 一种治疗亚急性甲状腺炎的药物 | |
| CN102526473B (zh) | 一种治疗慢性乙型病毒性肝炎的药剂 | |
| CN105617151A (zh) | 一种煮散型中药抗菌消炎剂及其制备方法和应用 | |
| CN102671178A (zh) | 一种治疗肾病综合症及尿毒症的中药组合物配制方法及应用 | |
| CN102114195B (zh) | 一种纯中药的戒毒胶囊 | |
| CN103142982A (zh) | 一种治疗急性上呼吸道感染的药剂 | |
| CN102670892A (zh) | 一种治疗少儿腹泻的药剂 | |
| CN102973758A (zh) | 一种治疗抑郁症的中药组合物 | |
| CN103055210A (zh) | 一种治疗痛风药(痛风定胶囊)及其加工方法 | |
| CN101264204A (zh) | 一种抑制尿酸治疗痛风的中药组合及其制备方法 | |
| CN102552511B (zh) | 一种治疗腹泻的药剂 | |
| CN102698064B (zh) | 一种治疗更年期综合征的药剂 | |
| CN112717084A (zh) | 治疗高泌乳素血症的中药组合物、制备方法及应用 | |
| CN102274423B (zh) | 一种治疗焦虑症的药剂 | |
| CN103191385B (zh) | 一种治疗小儿哮喘的药剂 | |
| CN102657744B (zh) | 一种治疗乳腺炎的药剂 | |
| CN101590206A (zh) | 一种治疗胆道结石的中药 | |
| CN101007113B (zh) | 一种有效治疗急慢性肝炎的参灵中药制剂及其制备方法 | |
| CN104162105A (zh) | 一种用于治疗乳痈的药物 | |
| CN104189562A (zh) | 一种治疗感冒后咳嗽的甘桑桔颗粒 | |
| CN104096184A (zh) | 一种治疗小儿睾丸鞘膜积液的中药 | |
| CN104189770A (zh) | 一种治疗结核性胸膜炎的药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIANG PHARMACEUTICAL INDUSTRY CO., LTD., JIANG Free format text: FORMER OWNER: ZHANG RONG Effective date: 20130730 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 273500 JINING, SHANDONG PROVINCE TO: 214400 WUXI, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130730 Address after: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee after: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin Address before: Department of General Hospital of Shandong Province, 273500 East infection in Zoucheng City Park Road 498, Yanzhou Mining Group Co Ltd Patentee before: Zhang Rong |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170505 Address after: 226500, No. 999, Wanshou South Road, Rugao City, Jiangsu province (room 3A08-26, building 8, hi tech Zone, Nantong) Patentee after: Jiangsu hundred sword Pharmaceutical Technology Co., Ltd. Address before: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee before: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130529 Termination date: 20190321 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |